Fig. 2
RAM-589.555 treatment ameliorates EAE clinical signs and reduces pathological parameters. a EAE clinical score following treatment with RAM-589.555. n = 10 mice/group; *p < 0.04. Disease incidence 90%. b Representative spinal cord sections (lumbar region) on day 17 after start of treatment stained with hematoxylin/eosin (H&E, upper panel), luxol fast blue (LFB, middle panel), and neurofilament (NF, lower panel) in adjacent longitudinal spinal cord sections, day 17 post-RAM-589.555 treatment. Score of mice taken for IHC illustration: vehicle-treated mouse with score 3 compared with RAM-589.555-treated mouse with score 0. Scale bar = 100 μm, c Mean number of inflammatory infiltrates per mm2 in adjacent longitudinal spinal cord sections. *p = 0.02. d The percentage of demyelinating areas in adjacent longitudinal spinal cord sections. *p = 0.007. e The percentage of axonal loss area in adjacent longitudinal spinal cord sections. *p = 0.03. In c–e n = 3 mice/group. The data presented are the mean ± SEM according to three independent experimental repeats